Abstract:Inhibition of the MDM2-p53 interaction is considered to be a new therapeutic strategy to activate wild-type p53 in tumors. Recently, a series of potent and specific small-molecule spiro-oxindole inhibitors of the MDM2 were reported. In the current study, the interaction modes between 21 spiro-oxindole MDM2 inhibitors and the protein were studied by using the combination of molecular docking, molecular dynamics simulation and three-dimensional quantitative structure-activity relationships (3D-QSAR). The QSAR predictive models were established by using comparative molecular field analysis (CoMFA) and comparative similarity indices analysis (CoMSIA) techniques. The predictive power of the 3D-QSAR models were determined from external test sets that were excluded during model development. The inhibitors in test sets were given exactly the same pretreatment as the inhibitors in the corresponding training sets. The correlation between the experimental and predicted activity for all models was calculated as a predictive r(2) value. With the CoMFA model, the cross-validated value (q(2)) was 0.573, the non-cross-validated value (r(2)) was 0.948. And with the CoMSIA model, the corresponding q(2) and r(2) were 0.651 and 0.98, respectively. The interaction mode obtained by molecular docking was in agreement with the results of molecular dynamics simulations, the interaction mode revealed that the hydrophobic interaction and H-bond played an important role in the binding of spiro-oxindole derivatives and MDM2. Compounds designed by our group were synthesized and tested their in vitro cytotoxic activities against the MDM2 positive prostatic carcinoma LNCaP cell line. Two compounds, namely 5 and 6, with favorable scores from the CoMFA and CoMSIA models, showed potent cytotoxic activities with IC50 values lower than 1.0 mu g.mL(-1). The result was corresponding with that in experiment. And it was very significance to discover novel spiro-oxindole inhibitors which are mainly aimed at the MDM2-p53 interaction. It was expected that the information provided here was helpful for the study toward more accurate structure based on 3D-QSAR modeling and anti-tumor drug design and discovery.

Design, synthesis, and biological evaluation of Nedd4 E3 ubiquitin ligase small molecule inhibitors

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Discovery of Nedd4 auto-ubiquitination inhibitors

Synthesis and Biological Evaluation of Novel Pyrimido[4,5-B]quinoline-2,4- Dione Derivatives As MDM2 Ubiquitin Ligase Inhibitors.

Design, synthesis, and biological evaluation of novel thieno[3,2-<i>d</i>]pyrimidine derivatives as potent antitumor agents

Identification of novel benzoyl hydrazine derivatives as activators of neddylation pathway to inhibit the tumor progression in vitro

Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold.

Insights Into the Biological Role of NEDD4L E3 Ubiquitin Ligase in Human Cancers

Discovery of the 2,4-Disubstituted Quinazoline Derivative As a Novel Neddylation Inhibitor for Tumor Therapy

Progress in the researches for antitumor NEDD8 activating enzyme inhibitors

Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors

Discovery of novel tertiary amide derivatives as NEDDylation pathway activators to inhibit the tumor progression <i>in vitro</i> and <i>in vivo</i>

Molecular Docking, QSAR and Molecular Dynamics Simulation on Spiro-oxindoles As MDM2 Inhibitors

Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction

Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth in vitro and in vivo

Design, Synthesis and Biological Evaluation of Bromophenol-Thiazolylhydrazone Hybrids Inhibiting the Interaction of Translation Initiation Factors Eif4e/eif4g As Multifunctional Agents for Cancer Treatment.

Design, synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitors.

Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.

Design, Synthesis and Biological Evaluation of Novel Antitumor Spirodihydrothiopyran-Oxindole Derivatives

Design,synthesis and in vitro activity study of a novel Bcl-2 protein inhibitors

Design, Synthesis, Antitumor Activity Evaluation, and Molecular Dynamics Simulation of Some 2-Aminopyrazine Derivatives